Celltrion and Samsung duel shaping up as both pledge billions of dollars to biologics

A biologics arms race of sorts appears to be shaping up in South Korea. Celltrion Chairman Seo Jung-jin said on Thursday that the conglomerate will spend about $33.6 billion on its pharma business over the next decade. The pledge comes just months after competitor Samsung said it will spend $22 billion in much the same way.